Abstracts tagged "B cell targeting"

Abstract Number: 1812 • 2015 ACR/ARHP Annual Meeting
The First Randomized Control Trial to Evaluate the Effectiveness of Bortezomib for Refractory Systemic Lupus Erythematosus
Tomonori Ishii¹, Yoshiya Tanaka², Atsushi Kawakami³, Kazuyoshi Saito², Kunihiro Ichinose⁴, Yuko Shirota⁵, Hiroshi Fujii⁵, Yoko Fujita⁶, Yukiko Kamogawa⁵, Tomoaki Machiyama⁵, Kanae Akita⁵ and Hideo Harigae⁵, ¹Department of Clinical Trial Implementation, Tohoku University Hospital, Clinical Research, Innovation and Education Center, Sendai, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ⁴Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ⁶Department of Hematolgy and Rheumatolgy, Tohoku University Graduate School of Medicine, Sendai, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease characterized by production and deposition of anti-dsDNA antibody. In recent years, treatment methods targeting antibody-producing B cell…
Abstract Number: 2139 • 2015 ACR/ARHP Annual Meeting
Results of a Phase 1b/2a Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XmAb®5871 in Patients with Rheumatoid Arthritis (RA)
Debra Zack¹, Maria Jaraczewska Baumann², Mariusz Korkosz³, Gabriella Suljok⁴, Petr Sramek⁵, Bernadette Rojkovich⁶, Stafan Daniluk⁷, Janos Bartalos⁸ and Paul Foster¹, ¹Xencor, Inc., San Diego, CA, ²NZOZ Centrum Medyczne HCP, Poznan, Poland, ³Malopolskie Centrum Medyczne, The University Hospital in Krakow, Krakow, Poland, ⁴Drug Research Center Ltd., Baltonfüred, Hungary, ⁵PRA CZ, Praha, Czech Republic, ⁶Polyclinic of the Hospitaller Brothers of St John of God, Budapest, Hungary, ⁷NZOZ Center of Osteoporosis and Osteoarticular Diseases, Bialystok, Poland, ⁸PRA Hungary Ltd, Budapest, Hungary
Background/Purpose: XmAb®5871 is a humanized Fc engineered monoclonal antibody that binds to the B cell restricted surface antigen CD19 and has enhanced Fc binding to…
Abstract Number: 2928 • 2014 ACR/ARHP Annual Meeting
Serum IL-33 Level Is Increased in Rheumatoid Arthritis and Predicts Response to Rituximab in Combination with High Serum IgG Level and Autoantibody Positivity: An Open-Label, Prospective, Multicentre Biological Trial
Jérémie Sellam¹, Houria Chavez², Stéphanie Rouanet³, Nathalie Vernet³, Bineta Ly⁴, Sandrine Marion-Thore⁵, Bernard Combe⁶, Jean Sibilia⁷, Jacques Tebib⁸, Gilles Chiocchia⁹, Maxime Dougados¹⁰, Yassine Taoufik² and Xavier Mariette¹¹, ¹AP-HP, Saint-Antoine Hospital, Rheumatology Department and DHU i2B, Paris, France, ²Biologic Immunology, Hopital Bicetre, Université Paris Sud, AP-HP, Kremlin Bicetre, France, ³Biostatistics, Roche France, Boulogne-Billancourt, France, ⁴INSERM U1012, Universite Paris-Sud, Kremlin Bicetre, France, ⁵INSERM U1016, Université Versailles Saint-Quentin, Montigny le Bretonneux, France, ⁶Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁷Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ⁸Rheumatology, University Hospital Lyon, Lyon, France, ⁹Université Versailles-Saint Quentin, Montigny le Bretonneux, France, ¹⁰INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ¹¹rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France
Background/Purpose . The recent discovered cytokine interleukin-33 (IL33) could be involved in B-cell activation as well as in RA pathophysiology. After a whole-blood transcriptomic analysis…
Abstract Number: 2874 • 2014 ACR/ARHP Annual Meeting
Pro-Inflammatory FcRL4+ Memory B Cells in Joints of RA Patients: Immunoglobulin Gene Characteristics and Antigen Specificity
Khaled Amara¹, Lorraine Yeo², Natalie Sippl¹, Philip Titcombe¹, Andrew Filer³, Karim Raza³, Dagmar Scheel-Toellner² and Vivianne Malmström⁴, ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, SE-17176 Solna, Stockholm, Sweden., Stockholm, Sweden, ²Rheumatology Research Group, Centre for Translational Inflammation Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK, Birmingham, United Kingdom, ³Rheumatology Research Group, MRC Centre for Immune Regulation, School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ⁴Medicine, Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Our recent findings identified a subset of pro-inflammatory memory B cells in the RA synovium characterized by the expression of the surface protein…
Abstract Number: 1955 • 2014 ACR/ARHP Annual Meeting
Disparity in Internalisation of Monoclonal Antibodies Targeting B Cell Antigens and Regulation By Fc Gamma Receptor IIb: Implications for Targeted Therapy in SLE
Venkat Reddy¹, Geraldine Cambridge², David A. Isenberg³, Mark Cragg⁴ and Maria J. Leandro², ¹Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁴Antibody and Vaccine group, Cancer Sciences Unit, Faculty of Medicine, Southampton University, Southampton, United Kingdom
Background/Purpose Monoclonal antibodies (mAbs) targeting B cell antigens CD20 and CD22 are used to treat patients with SLE either in the clinic or in clinical…
Abstract Number: 1495 • 2014 ACR/ARHP Annual Meeting
Preclinical and Clinical Phase I Profile of MK-8457, a Selective Spleen Tyrosine Kinase and Zeta-Chain-Associated Protein Kinase 70 Inhibitor, Developed for the Treatment of Rheumatoid Arthritis
Gene Marcantonio¹, Alan Bass², Gretchen Baltus³, Judith Boice¹, Hongmin Chen⁴, Michael Crackower⁵, Jeroen Elassaiss-Schaap⁶, Michael Ellis⁷, Tomoko Freshwater⁸, Francois Gervais⁹, Jane Guo¹⁰, Sammy Kim⁹, Lily Moy⁵, Alan Northrup⁷, Jie Zhang-Hoover⁴, Mathew Maddess¹¹, Richard Miller¹², Marcella Ruddy⁵, Stella Vincent¹³, Haoling Weng¹ and Hani Houshyar¹⁴, ¹Merck & Co., Whitehouse Station, NJ, ²Safety Assessment, Merck & Co., Boston, MA, ³Immunomodulatory Regulators, Merck & Co., Boston, MA, ⁴Pharmacology, Merck & Co., Boston, MA, ⁵Merck & Co., Boston, MA, ⁶Clinical PK-PD, Merck & Co., Oss, Netherlands, ⁷Medicinal Chemistry, Merck & Co., Boston, MA, ⁸PPDM Early Stage, Merck & Co., Rahway, NJ, ⁹Cell Pathways and Proteins, Merck & Co., Boston, MA, ¹⁰Immunology, Merck & Co., Boston, MA, ¹¹Discovery Process Chemistry, Merck & Co., Boston, MA, ¹²Biochemistry & Biophysics, Merck & Co., Boston, MA, ¹³PPDM Preclinical ADME, Merck & Co., Boston, MA, ¹⁴33 Avenue Louis Pasteur, Merck & Co., Boston, MA
Background/Purpose: Spleen tyrosine kinase (SYK) is a potential target for treatment of several diseases including rheumatoid arthritis. SYK is a member of the Zeta-chain-associated protein…
Abstract Number: 452 • 2014 ACR/ARHP Annual Meeting
The Use of Multiplex Bead Array to Follow the Effect of Rituximab on IgG and IgA Serum Autoantibody Responses to Citrullinated Epitopes in Patients with Rheumatoid Arthritis
Geraldine Cambridge¹, Lauren J. Lahey², Maria J. Leandro¹, William H. Robinson² and Jeremy Sokolove², ¹Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ²VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA
Background/Purpose The majority of patients with established Rheumatoid arthritis (RA) have autoantibodies against the Fc of IgG (Rheumatoid factors-RhF) and to citrullinated protein antigens (ACPAs).…
Abstract Number: 2234 • 2013 ACR/ARHP Annual Meeting
Targeting Therapy Of Citrullinated Antigen-Specific B Cells Ameliorates Collagen-Induced Arthritis
Kazuya Michishita¹, Kimito Kawahata¹, Takeyuki Kanzaki², Lisa Akahira¹, Toshiki Eri¹ and Kazuhiko Yamamoto³, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Internal Medicine, Yamanashi Prefectural Central Hospital, Yamanashi, Japan, ³Department of Allergy and Rhaumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: The clinical benefit of B-cell depletion therapy in rheumatoid arthritis(RA) is a well-known fact, but problems such as relapse of tuberculosis and reactivation of…
Abstract Number: 1432 • 2013 ACR/ARHP Annual Meeting
The Rate Of Serious Infections Remains Stable In Patients With Multiple Retreatments In Real life : Data From The “Auto Immunity and Rituximab” (AIR) Registry
Jacques-Eric Gottenberg¹, Philippe Ravaud², Patrice Cacoub Sr.³, Thomas Bardin⁴, Alain G. Cantagrel⁵, Bernard Combe⁶, Maxime Dougados⁷, Rene-Marc Flipo⁸, Bertrand Godeau⁹, Loic Guillevin¹⁰, Xavier Le Loet¹¹, Eric Hachulla¹², Thierry Schaeverbeke¹³, Jean Sibilia¹⁴, Isabelle Pane¹⁵, Gabriel Baron¹⁶ and Xavier Mariette¹⁷, ¹Strasbourg University Hospital, Strasbourg, France, ²Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ³Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France, ⁴Rhumatology Departement, Hôpital Lariboisière, Paris, France, ⁵Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France, ⁶Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁷Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁸Rheumatology, Hopital R Salengro CHRU, Lille, France, ⁹Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, ¹⁰Department of Internal Medicine,, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹¹Rheumatology Department, CHU of ROUEN, Rouen, France, ¹²Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹³Rhumatology departement, Groupe Hospitalier Pellegrin, Bordeaux, France, ¹⁴Rhumatologie, CHU Hautepierre, Strasbourg, France, ¹⁵Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹⁶Epidemiology & Clinical Research, Groupe Hospitalier Bichat-Claude Bernard, Paris, France, ¹⁷Rheumatology Departement, Bicêtre University Hospital, Paris, France
Background/Purpose: Serious infections in patients with rheumatoid arthritis (RA) treated with rituximab (RTX) are slightly more frequent in common practice than in clinical trials. Morevover,…
Abstract Number: 922 • 2013 ACR/ARHP Annual Meeting
Role Of B Cells and/Or Autoantibodies In Pulmonary Manifestations Of Inflammatory Arthritis
Lisa K. Peterson¹, Jeremy Sokolove², Paul Jedlicka³, Lauren J. Lahey⁴, William H. Robinson⁵ and Leonard L. Dragone⁶, ¹Pediatrics, National Jewish Health, Denver, CO, ²VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ³Pathology, University of Colorado Denver, Aurora, CO, ⁴Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁵VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁶Dept of Pediatrics, National Jewish Health, Denver, CO
Background/Purpose: RA is a systemic condition affecting approximately 1% of the general population leading to progressive arthritis and extra-articular manifestations (ExRA), including interstitial lung disease…
Abstract Number: 38 • 2013 ACR/ARHP Annual Meeting
Use Of An In Vitro Whole Blood Depletion ASSAY To Compare The Efficacy Of B CELL Depleting Agents In Patients With Systemic LUPUS Erythematosus
Venkat Reddy¹, Geraldine Cambridge², D.A. Isenberg³, Mark Cragg⁴ and Maria Leandro⁵, ¹Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Centre for Rheumatology Research, University College London, London, United Kingdom, ⁴Antibody and Vaccine group, Cancer Sciences Unit, Faculty of Medicine, Southampton University, Southampton, United Kingdom, ⁵Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Variability in clinical response to B-cell depletion therapy (BCDT) with the anti-CD20mAb rituximab (RTX) has been well described in Systemic Lupus Erythematosus (SLE). Poor…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].